Holmium laser en‑bloc vs bipolar and conventional monopolar TURBT for non‑muscle‑ınvasive bladder cancer
International Urology and Nephrology · 2026
DOI: 10.1007/s11255-026-05023-5 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift International Urology and Nephrology, 2026. Verfasst von Aykut Aykaç und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Health Science University Eskisehir City Health Application and Research Center, Eskisehir, Türkiye. Hauptthemen laut MEDLINE: Transurethral Resection of Bladder, Lasers, Solid-State, Non-Muscle Invasive Bladder Neoplasms, Laser Therapy. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: This study aimed to compare the clinical safety, surgical efficacy, and oncologic outcomes of three transurethral resection techniques: the conventional monopolar transurethral resection of bladder tumor (CM-TURBT), the bipolar transurethral resection of bladder tumor (BP-TURBT), and the holmium laser en bloc resection of bladder tumor (HoL-ERBT) in patients with primary non-muscle-invasive bladder cancer (NMIBC). METHODS: This retrospective single-center cohort study included consecutive patients with primary NMIBC treated between January 2020 and March 2025. All eligible patients undergoing CM-TURBT, BP-TURBT, or HoL-ERBT were analyzed. To minimize confounding related to non-random treatment allocation, the inverse probability of treatment weighting (IPTW) based on propensity scores was applied. Perioperative outcomes, complication rates, detrusor muscle inclusion, visible complete resection, and recurrence-free survival (RFS) were compared using weighted analyses. Time-to-event outcomes were assessed with IPTW-adjusted Kaplan-Meier curves and Cox regression models. RESULTS: After IPTW adjustment, HoL-ERBT was associated with significantly shorter resection times, lower hematuria rates, and reduced catheterization and hospitalization durations compared with CM-TURBT (p < 0.001 for all), while BP-TURBT demonstrated intermediate outcomes. Detrusor muscle inclusion was highest with HoL-ERBT (approximately 93%), compared with CM-TURBT (≈ 66%) and BP-TURBT (≈ 77%). IPTW-adjusted RFS at 12, 24, and 36 months did not differ significantly among the techniques. CONCLUSION: HoL-ERBT provides meaningful perioperative and pathological advantages over conventional TURBT techniques in NMIBC without compromising short- to mid-term oncologic outcomes. To our knowledge, this is the first study with a follow-up period exceeding 24 months. Despite procedural advantages, similar recurrence outcomes suggest that further prospective randomized trials are warranted to clarify the long-term oncologic role of HoL-ERBT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Health Science University Eskisehir City Health Application and Research Center, Eskisehir, Türkiye.
- Department of Urology, Health Science University Eskisehir City Health Application and Research Center, Eskisehir, Türkiye. sevmus2005@gmail.com.
- Tepebasi District Health Directorate, Public Health Expertise, Eskisehir, Türkiye.
ORCID-Profile: Aykut Aykaç, Coşkun Kaya, Mustafa Sungur, Mehmet Erhan Aydın, Sevda Sungur
Zitieren
APA
Aykaç, A., Kaya, C., Sungur, M., Aydın, M. E., & Sungur, S. (2026). Holmium laser en‑bloc vs bipolar and conventional monopolar TURBT for non‑muscle‑ınvasive bladder cancer. International Urology and Nephrology. https://doi.org/10.1007/s11255-026-05023-5
Vancouver
Aykaç A, Kaya C, Sungur M, Aydın ME, Sungur S. Holmium laser en‑bloc vs bipolar and conventional monopolar TURBT for non‑muscle‑ınvasive bladder cancer. International Urology and Nephrology. 2026. doi:10.1007/s11255-026-05023-5
BibTeX
@article{Ayka2026,
author = {Aykaç, Aykut and Kaya, Coşkun and Sungur, Mustafa and Aydın, Mehmet Erhan and Sungur, Sevda},
title = {Holmium laser en‑bloc vs bipolar and conventional monopolar TURBT for non‑muscle‑ınvasive bladder cancer},
journal = {International Urology and Nephrology},
year = {2026},
doi = {10.1007/s11255-026-05023-5}
}
EUVIMED